IgM antibody to hepatitis C virus in acute and chronic hepatitis C

Open Access
Publisher Website
Google Scholar
Abstract
To assess possible role of testing for IgM-specific antibody in the diagnosis and monitoring of patients with hepatitis C, we tested sera from 14 patients with acute and 97 patients with chronic non-A, non-B hepatitis for IgG and IgM antibody to hepatitis C virus. IgG antibody to hepatitis C virus was detected in 93% of acute cases and 91% of chronic cases. Of the 101 patients with IgG antibody to hepatitis C virus, 57% had IgM antibody to hepatitis C virus. None of the 20 healthy subjects or 40 patients with acute or chronic hepatitis A or hepatitis B had IgM antibody to hepatitis C virus. At the onset of clinical symptoms in acute hepatitis C, IgG antibody to hepatitis C virus was detected in 8 (57%) and IgM antibody to hepatitis C virus in 9 of 14 patients (64%). Eventually, both IgG and IgM antibody to hepatitis C virus became detectable in 13 of 14 patients with acute hepatitis C. Seven patients with antibody to hepatitis C virus resolved the acute infection within 6 mo and all seven cleared IgM antibody to hepatitis C virus, whereas two cleared IgG antibody to hepatitis C virus. Six patients had a chronic outcome of the acute infection and IgM antibody to hepatitis C virus persisted in detectable amounts for more than 6 mo in all (mean = 15.5 mo). Among 88 patients with chronic non-A, non-B hepatitis with IgG antibody to hepatitis C virus, IgM antibody to hepatitis C virus was detected in 45(51%). Twenty-four chronic cases were followed for at least 1 yr: IgM antibody to hepatitis C virus was detected in 13 (54%) at baseline and 8 of these remained positive for at least 1 yr. Patients who lost IgM antibody to hepatitis C virus did not have remission of disease activity. In summary, IgM antibody to hepatitis C virus persists after acute infection in patients who contract chronic hepatitis C; therefore, testing for this antibody may be useful in early identification of patients for antiviral therapy. (HEPATOLOGY 1991;14:38-43.)